

REMARKS

In the Restriction Requirement mailed October 21, 2009, the claims of the above-identified patent application were restricted as follows:

Group I, Claims 1-6, 9-10, 13 and 15-19 drawn to a compound of formula (I);

Group II, Claim 7, drawn to a method of treatment of disease associated with thyroid receptor activity in mammal by administering effective amount of compound of formula (I);


Group III, Claim 12, drawn to a method of discovering a ligand of the thyroid hormone receptor by using a compound of formula (I); and

Group IV, Claim 14, drawn to a method for preparing a compound of formula (I).

Applicants herein elect, without traverse, the claims of Group I (claims 1-6, 9-10, 13, and 15-19) for further prosecution at this time. Applicants reserve the right to file Divisional applications on the unelected claims pursuant to 35 U.S.C. §120 and §121.

Species Election

The Examiner also requested Applicants to elect a single specific species of the generic invention. In response, Applicants herein elect, without traverse, the compound described in Example 54 for search purposes:



3-(3,5-dibromo-4-(3-chloro-5-(methylsulfonamido)benzyloxy)phenyl)-2-fluoropropanoic acid

Applicants submit that claims 1-6, 9-10, 13, and 15-19 read on the elected species.

If the Examiner has any questions concerning this application, the Examiner is encouraged to contact the undersigned attorney.

Please charge any fees due with this response to Deposit Account 23-1665 under
Customer Number 27267.

Respectfully submitted,

Ana Maria Garcia Collazo et al.

By Todd E. Garabedian

Todd E. Garabedian, Ph.D.

Registration No. 39,197

Attorney for Applicants

WIGGIN and DANA LLP
One Century Tower
New Haven, CT 06508
Telephone: (203) 498-4400
Facsimile: (203) 782-2889

Date: 18 Nov 2009